Cepheid Prelim Q3 Revenues Miss Top, Bottom Lines; Firm Lowers Full-Year Guidance | GenomeWeb

NEW YORK (GenomeWeb) – Cepheid said after the close of the market on Tuesday that it expects to miss analysts' consensus estimates on both the top and bottom lines in the third quarter due primarily to lower-than-expected gross margin.

For the quarter ended Sept. 30, Cepheid reported preliminary revenue of approximately $126.5 million, shy of the Wall Street estimate of $127.8 million. Net loss per share, meantime, is expected to be $.32 in the quarter, falling short of analysts' estimate of a $.26 loss per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.